Tobam I Mab Transaction History

Tobam

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 02, 2022	SELL	$8.27 - $18.43 $1.24 Million - $2.77 Million	-150,200 Closed	0 $0
Q1 2022 Apr 25, 2022	SELL	$12.54 - $46.93 $555,522 - $2.08 Million	-44,300 Reduced 22.78%	150,200 $2.44 Million
Q4 2021 Feb 15, 2022	BUY	$45.28 - $74.5 $122,256 - $201,150	2,700 Added 1.41%	194,500 $9.22 Million
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $2.49 Million - $3.67 Million	43,500 Added 29.33%	191,800 $13.9 Million
Q2 2021 Aug 11, 2021	BUY	$47.86 - $83.95 $7.1 Million - $12.4 Million	148,300 New	148,300 $12.5 Million

15.9M

1.9K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $98.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Tobam, based on Form 13F filings with the SEC.

Stay updated on Tobam with notifications on news.